“
TL;DR
The authors highlight both the promise and the significant technical, safety, regulatory, and ethical challenges that must be addressed before iPSC-based cancer therapies can be widely adopted.
Molecular Cancer · 14 authors, 9 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The authors highlight both the promise and the significant technical, safety, regulatory, and ethical challenges that must be addressed before iPSC-based cancer therapies can be widely adopted.
The review also addresses significant limitations, including the risk of genomic instability and tumorigenicity during reprogramming, inefficiency of iPSC generation, regulatory and safety challenges in clinical translation, and ethical concerns surrounding cell sourcing and commercial exploitation. Implications are speculative, pointing toward the need for safer reprogramming methods, rigorous safety assessments, and regulatory frameworks.